Extracellular signal-regulated kinase (ERK1/2) contributes to endotoxin-induced hyporeactivity via nitric oxide and prostacyclin production in rat aorta

Pharmacology

Volumn 78, Issue 3, 2006, Pages 123-128

  Korkmaz, Belma ^a   Ozveren, Elif ^a   Buharalioglu, Cuneyt Kemal ^a   Tunctan, Bahar ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Aorta, rat; Endotoxin; Extracellular signal regulated kinase; Nitric oxide; Prostacyclin; Vascular hyporeactivity

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 6 OXOPROSTAGLANDIN F1 ALPHA; ENDOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NORADRENALIN; PHENYLENE 1,3 BIS(ETHANE 2 ISOTHIOUREA)DIHYDROBROMIDE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVATION; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; ENZYME ACTIVATION; EPOPROSTENOL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PHOSPHORYLATION; RATS; RATS, WISTAR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 33751099810     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095962     Document Type: Article

References (50)

1. Tslotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J: Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit 2005;11:RA76-RA85.
2. Grissom TE, Bina S, Hart J, Muldoon SM: Effect of phenylephrine-induced vascular smooth muscle contractions in endotoxin-exposed rat aortic rings. Crit Care Med 1996;24:287-293.
3. McKenna TM, Martin FM, Chernow B, Briglia FA: Vascular endothelium contributes to decreased aortic contractility in experimental sepsis. Circ Shock 1986;19:267-273.
4. Nakaki T, Otsuka Y, Nakayama M, Kato R: Endothelium-accelerated hyporesponsiveness of norepinephrine-elicited contraction of rat aorta in the presence of bacterial lipopolysaccharide. Eur J Pharmacol 1992;219:311-318.
5. Wileman SM, Mann GE, Baydoun AR: Induction of L -arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of proinflammatory cytokines and bacterial lipopolysaccharide. Br J Pharmacol 1995;116:3243-3250.
6. Wylam ME, Metkus AP, Umans JG: Nitric oxide dependent and independent effects of in vitro incubation or endotoxin on vascular reactivity in rat aorta. Life Sci 2001;69:455-467.
7. Zhou J, Struthers AD, Lyles GA: Differential effects of some cell signalling inhibitors upon nitric oxide synthase expression and nuclear factor-kappaB activation induced by lipopolysaccharide in rat aortic smooth muscle cells. Pharmacol Res 1999;39:363-373.
8. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990;259:H1038-H1043.
9. Suba EA, McKenna TM, Williams TJ: In vivo and in vitro effects of endotoxin on vascular responsiveness to norepinephrine and signal transduction in the rat. Circ Shock 1992;36:127-133.
10. Thiemermann C: The role of the L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 1994;28:45-79.
11. Turini ME, DuBois RN: Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35-57.
12. 2 antagonist SQ29,548 impair in vitro contractions of aortic rings of ex vivo-treated lipopolysaccharide rats. J Lipid Mediat Cell Signal 1996;13:177-187.
13. Fatehi-Hassanabad Z, Muller B, Andriantsitohaina R, Furman BL, Parratt JR, Stoclet JC: Influence of indomethacin on the haemodynamic effects of lipopolysaccharide in rats. Fundam Clin Pharmacol 1996;10:258-263.
14. Gray GA, Furman BL, Parratt JR: Endotoxin-induced impairment of vascular reactivity in the pithed rat: role of arachidonic acid metabolites. Circ Shock 1990;31:395-406.
15. Hoefen RJ, Berk BC: The role of MAP kinases in endothelial activation. Vascul Pharmacol 2002;38:271-273.
16. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
17. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG: A role for MAP kinase differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation. Am J Physiol 1998;275:C1081-C1086.
18. Khalil RA, Menice CB, Wang CL, Morgan KG: Phosphotyrosine-dependent targeting of mitogen-activated protein kinase in differentiated contractile vascular cells. Circ Res 1995;76:1101-1108.
19. Kwon S, Lee WJ, Fang LH, Kim B, Ahn HY: Mitogen-activated protein kinases partially regulate endothelin-1-induced contractions through a myosin light chain phosphorylation-independent pathway. J Vet Med Sci 2003;65:225-230.
20. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL: Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 1999;84:505-515.
21. Hague C, Gonzalez-Cabrera PJ, Jeffries WB, Abel PW: Relationship between alpha(1)-adrenergic receptor-induced contraction and extracellular signal-regulated kinase activation in the bovine inferior alveolar artery. J Pharmacol Exp Ther 2002;303:403-411.
22. Ratz PH: Regulation of ERK phosphorylation in differentiated arterial muscle of rabbits. Am J Physiol 2001;281:H114-H123.
23. Ward DT, Alder AC, Ohanian J, Ohanian V: Noradrenaline-induced paxillin phosphorylation, ERK activation and MEK-regulated contraction in intact rat mesenteric arteries. J Vasc Res 2002;39:1-11.
24. Watts SW: 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogenactivated protein kinase pathway dependent. Hypertension 2000;35:244-248.
25. Dong C, Davis RJ, Flavell RA: MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
26. Yamakawa T, Eguchi S, Matsumoto T, Yamakawa Y, Numaguchi K, Miyata I, Reynolds CM, Motley ED, Inagami T: Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-kappaB and p38 mitogen-activated protein kinase on tumor necrosis factor-alpha production. Endocrinology 1999;140:3562-3572.
27. Jiang B, Brecher P, Cohen RA: Persistent activation of nuclear factor-kappaB by interleukin-1beta and subsequent inducible NO synthase expression requires extracellular signal-regulated kinase. Arterioscler Thromb Vasc Biol 2001;21:1915-1920.
28. Kim B, Kim J, Kim A, Kim YS, Lee YR, Bae YM, Cho S, Rhyu MR: Ligusticum wallichi-induced vasorelaxation mediated by mitogen-activated protein kinase in rat aortic smooth muscle. J Ethnopharmacol 2004;90:397-401.
29. Tunctan B, Korkmaz B, Ozveren E, Buharalioglu CK: Mitogen-activated protein kinase signalling cascade contributes to endotoxin-induced hyporeactivity via nitric oxide and prostaglandin production in rat thoracic aorta. FASEB J 2005;19(suppl):A1551.
30. Tunctan B, Altug S, Uludag O, Abacioglu N: Effects of econazole on receptor-operated and depolarization-induced contractions in rat isolated aorta. Life Sci 2000;67:2393-2401.
31. Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Paith JE, Furfine ES: Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem 1994;269:26669-26676.
32. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
33. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
34. Tunctan B, Uludag O, Altug S, Abacioglu N: Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. Pharmacol Res 1998;38:405-411.
35. Rosenkranz B, Fischer C, Reimann I, Weimer KE, Beck G, Frolich JC: Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man. Biochim Biophys Acta 1980;619:207-213.
36. Fink MP, Nelson R, Roethel R: Low-dose dopamine preserves renal blood flow in endotoxin shocked dogs treated with ibuprofen. J Surg Res 1985;38:582-591.
37. Sakamoto A, Matsumura J, Mii S, Gotoh Y, Ogawa R: A prostaglandin E 2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock 2004;22:76-81.
38. Beasley D, Cohen RA, Levinsky NG: Endotoxin inhibits contraction of vascular smooth muscle in vitro. Am J Physiol 1990;258:H1187-H1192.
39. Perez-Sala D, Lamas S: Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid Redox Signal 2001;3:231-248.
40. Liu SF, Adcock IM, Old RW, Barnes PJ, Evans TW: Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit Care Med 1996;24:1219-1225.
41. Liu SF, Newton R, Evans TW, Barnes PJ: Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci 1996;90:301-306.
42. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D: Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005;57:217-252.
43. Koshimizu TA, Tanoue A, Hirasawa A, Yamauchi J, Tsujimoto G: Recent advances in alpha1-adrenoceptor pharmacology. Pharmacol Ther 2003;98:235-244.
44. Kahwaji CI, Sheibani S, Han S, Siu WO, Kaka AH, Fathy TM, el-Abbadi NH, Purdy RE: Evidence that simulated microgravity may alter the vascular nonreceptor tyrosine kinase second messenger pathway. Proc West Pharmacol Soc 2000;43:75-77.
45. Komalavilas P, Shah PK, Jo H, Lincoln TM: Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999;274:34301-34309.
46. Pilz RB, Broderick KE: Role of cyclic GMP in gene regulation. Front Biosci 2005;10:1239-1268.
47. Schindler H, Bogdan C: NO as a signaling molecule: effects on kinases. Int Immunopharmacol 2001;1:1443-1455.
48. Martens FM, Demeilliers B, Girardot D, Daigle C, Dao HH, deBlois D, Moreau P: Vessel-specific stimulation of protein synthesis by nitric oxide synthase inhibition: role of extracellular signal-regulated kinases 1/2. Hypertension 2002;39:16-21.
49. Borsch-Haubold AG, Pasquet S, Watson SP: Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998;273:28766-28772.
50. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.